Table 2.
Spearman correlation analysis of SARS-CoV-2-specific IgG antibodies and SARS-CoV-2-specific ELISpot responses in 117 patients after hematopoietic stem cell transplantation (HSCT) and in 35 healthy controls, after two SARS-CoV-2 vaccinations.
| Cohort | Antigen for ELISpot | r | p |
|---|---|---|---|
| HSCT | S1 | 0.45 | <0.0001 |
| S1/S2 | 0.22 | 0.02 | |
| S Sino | 0.16 | 0.09 | |
| Spike (T-SPOT.COVID) 1 | 0.52 | 0.04 | |
| Healthy controls | S1 | 0.22 | 0.22 |
| S1/S2 | 0.20 | 0.25 | |
| S Sino | 0.40 | 0.02 | |
| Spike (T-SPOT.COVID) 1 | 0.14 | 0.64 |
1 T-SPOT.COVID (Oxford Immunotec, OI) using the spike antigen was only performed in 17 patients and 13 healthy controls. S1-peptide mix of the SARS-CoV-2 spike (S) 1; S1/S2-peptide mix of the spike (S) 1 and S2; S Sino-S1 protein (Sino Biological).